TOI

The Oncology Institute Inc. (TOI) | Rumor.io

The Oncology Institute

TOI

Attention (50-day avg)0%

Attention rank (50-day avg)#2,606

Bullish sentiment (50-day avg)100%

Price to earnings ratio-12.3

Market capitalization665.9M

Earnings per share-0.35

Dividend yield (TTM)—

Revenue (annual)502.7M

Net income (annual)-60.6M

Social

What share of all stock conversation is about TOI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0.01% +0

Jul 9

TOI is considered a potential 10+ bagger with a higher chance of significant returns compared to Constellation Software (CSU).
The company's lower valuation and depressed stock price may be due to its focus on paying off debt and acquiring smaller companies, rather than pursuing major deals.
TOI's European operations and structural barriers may provide a competitive advantage, leading to higher organic growth rates and making it a more attractive investment option.

Generated by AI

Sentiment

Of the messages about TOI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	97.48% +6.3
Bearish	—	—	—	2.52% -6.3

Bullish· Mar 13

$TOI's Q4 results showed a narrower loss and strong revenue growth, with revenue up 42% year-over-year, beating expectations.
The company's growth in Capitated revenue and the expansion of its capitated TAM within Florida are key positives, with the potential for significant flow-through to dispensing.
$TOI's robust FCF margin of 22% and balance sheet fortress position make it an attractive investment opportunity, with the potential for double-digit returns.

Bearish· Feb 12

The Oncology Institute, Inc. (TOI) is among the tech stocks crashing, according to recent market trends.
The company's stock price may be impacted by the broader tech sector downturn, potentially leading to further losses.
TOI's stock is being sold by investors as part of a larger strategy to shift their portfolios away from declining tech stocks.

Generated by AI

Topics

Of the messages about TOI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	0.58%
Macro	—	—	0%	49.79%
Earnings	—	—	0%	0.1%
Technical Analysis	—	—	0%	0.18%
Analysts	—	—	0%	49.35%
Controversies	—	—	0%	0%

Announcements· Apr 25

TOI's report on India-Pakistan tensions may lead to a limited airstrike on Pakistan, as per a senior military official.
The possibility of a limited airstrike is being considered by New Delhi, with military options being weighed by the government.
TOI's stock has surged 900% YTD, according to a recent reply.

Macro· Apr 25

The Oncology Institute, Inc. (TOI) is not the main subject of this post, which discusses India-Pakistan tensions and potential military actions.
The post does mention TOI in passing, as it is the ticker symbol of the Times of India newspaper, but it is not the primary focus of the discussion.
Macro market implications of the India-Pakistan tensions are not discussed in this post, so there is no relevant information to summarize.

Technical Analysis· Mar 13

$TOI is trying to break out previous resistance, with some concern that it may be a false breakout.
$TOI has printed a wave 5 top at 148.88, and a violent wave A flush back to the 134.42 support is expected.
$TOI is testing key Fibonacci resistance, with volume confirming interest in the stock.

Generated by AI

Community

Of the messages about TOI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	200%	100%	96%	7.33%
Newcomers	-100%	0%	4%	92.67%

Regulars· Nov 14

TOI's 3Q25 revenue beat expectations, with a 36.7% increase to $136.6M, and guidance was raised for 2025 revenue to $495–505M.
Ascertain partners with TOI on an AI automation system, potentially driving future growth.
TOI's price surge is being closely watched, with a 28% gain and sustained interest in the stock, particularly above its intraday VWAP.

Newcomers· Jul 9

Newcomers to TOI are comparing it to Constellation Software (CSU) and Topicus, highlighting TOI's potential for acquiring companies at lower multiples.
They are considering factors such as competition, deal size, and historical PE multiples in the USA and Europe, with some doubting TOI's risk level.
Some users are evaluating TOI's potential for long-term growth, including the possibility of becoming a 10+ bagger in a shorter timespan, and are considering its historical record of acquisitions compared to CSU.

Generated by AI

News

Starling Oncology Institute Secures New $25 Million Credit Facility

Tipranks Press Release.

1mo agoThe Globe and Mail

Oncology Institute Q2 Earnings Call Highlights

Oncology Institute (NASDAQ:TOI) reported second-quarter revenue growth, positive adjusted EBITDA and an expanded pipeline of value-based oncology contracts as the company announced it has rebranded as Starling Oncology. Chief Executive Officer Dan Virnich said the new name reflects the company’s ev

1mo agoYahoo Finance

The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates

1mo agoYahoo Finance

Earnings To Watch: Starling Oncology Inc (STLN) Q2 2026 -- GF Value Sees 44% Downside

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

1mo agoYahoo Finance

The Oncology Institute Changes Name to Starling Oncology

1mo agoYahoo Finance

The Oncology Institute Rebrands as Starling Oncology

Company to begin trading on Nasdaq under new ticker symbol “STLN,” replacing “TOI”CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced today that it has rebranded to “Starling Oncology, Inc.™.” The Company's common stock will begin trading under the new ticker symbol "STLN” on Nasdaq, effective August 4, 2026, replacing its previous ticker symbol “TOI.” “We've spen

1mo agoYahoo Finance

Also Discussed

Investors talking about TOI also mention

#	Name	Attention
1	CSU - Capital Senior Living Corporation	——
2	Invesco Ultra Short Duration ETFGSY	0%new
3	Kinsale Capital Group, Inc.KNSL	0%0
4	Copart, Inc.CPRT	0%-0.01
5	NVEI - Nuvei Corporation	——
6	TFI International Inc.TFII	0%new
7	Valhi Inc.VHI	0%0
8	Open Text Corp.OTEX	0%0
9	TruBridge, Inc.TBRG	0%0
10	Brookfield Asset Management Ltd. Class A Limited Voting SharesBAM	0.02%new

The Oncology Institute Inc.

Healthcare
Medical Care Facilities

The Oncology Institute, Inc. is a value-based community oncology group providing comprehensive cancer care treatment services across multiple settings. Operating through three primary segments—Dispensary, Patient Care, and Clinical Trials and Other—the company delivers specialized oncology services including infusion centers, in-house pharmaceutical dispensary, outpatient blood transfusions, outpatient stem cell transplants, financial counseling, clinical trials, comprehensive laboratory testing, and end-of-life counseling. With over 100 employed clinicians and more than 800 team members operating across numerous clinic locations, The Oncology Institute serves a large patient population with evidence-based, high-quality cancer care. Founded in 2007 and headquartered in Cerritos, California, the company focuses on advancing oncology through value-based care models designed to improve patient outcomes while optimizing healthcare delivery in community settings rather than traditional hospital environments.

Website

Location

18000 Studebaker Road

Cerritos, CA, 90703

United States

Social

What share of all stock conversation is about TOI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0.01% +0

Jul 9

TOI is considered a potential 10+ bagger with a higher chance of significant returns compared to Constellation Software (CSU).
The company's lower valuation and depressed stock price may be due to its focus on paying off debt and acquiring smaller companies, rather than pursuing major deals.
TOI's European operations and structural barriers may provide a competitive advantage, leading to higher organic growth rates and making it a more attractive investment option.

Generated by AI

Sentiment

Of the messages about TOI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	97.48% +6.3
Bearish	—	—	—	2.52% -6.3

Bullish· Mar 13

$TOI's Q4 results showed a narrower loss and strong revenue growth, with revenue up 42% year-over-year, beating expectations.
The company's growth in Capitated revenue and the expansion of its capitated TAM within Florida are key positives, with the potential for significant flow-through to dispensing.
$TOI's robust FCF margin of 22% and balance sheet fortress position make it an attractive investment opportunity, with the potential for double-digit returns.

Bearish· Feb 12

The Oncology Institute, Inc. (TOI) is among the tech stocks crashing, according to recent market trends.
The company's stock price may be impacted by the broader tech sector downturn, potentially leading to further losses.
TOI's stock is being sold by investors as part of a larger strategy to shift their portfolios away from declining tech stocks.

Generated by AI

Topics

Of the messages about TOI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	0.58%
Macro	—	—	0%	49.79%
Earnings	—	—	0%	0.1%
Technical Analysis	—	—	0%	0.18%
Analysts	—	—	0%	49.35%
Controversies	—	—	0%	0%

Announcements· Apr 25

TOI's report on India-Pakistan tensions may lead to a limited airstrike on Pakistan, as per a senior military official.
The possibility of a limited airstrike is being considered by New Delhi, with military options being weighed by the government.
TOI's stock has surged 900% YTD, according to a recent reply.

Macro· Apr 25

The Oncology Institute, Inc. (TOI) is not the main subject of this post, which discusses India-Pakistan tensions and potential military actions.
The post does mention TOI in passing, as it is the ticker symbol of the Times of India newspaper, but it is not the primary focus of the discussion.
Macro market implications of the India-Pakistan tensions are not discussed in this post, so there is no relevant information to summarize.

Technical Analysis· Mar 13

$TOI is trying to break out previous resistance, with some concern that it may be a false breakout.
$TOI has printed a wave 5 top at 148.88, and a violent wave A flush back to the 134.42 support is expected.
$TOI is testing key Fibonacci resistance, with volume confirming interest in the stock.

Generated by AI

Community

Of the messages about TOI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	200%	100%	96%	7.33%
Newcomers	-100%	0%	4%	92.67%

Regulars· Nov 14

TOI's 3Q25 revenue beat expectations, with a 36.7% increase to $136.6M, and guidance was raised for 2025 revenue to $495–505M.
Ascertain partners with TOI on an AI automation system, potentially driving future growth.
TOI's price surge is being closely watched, with a 28% gain and sustained interest in the stock, particularly above its intraday VWAP.

Newcomers· Jul 9

Newcomers to TOI are comparing it to Constellation Software (CSU) and Topicus, highlighting TOI's potential for acquiring companies at lower multiples.
They are considering factors such as competition, deal size, and historical PE multiples in the USA and Europe, with some doubting TOI's risk level.
Some users are evaluating TOI's potential for long-term growth, including the possibility of becoming a 10+ bagger in a shorter timespan, and are considering its historical record of acquisitions compared to CSU.

Generated by AI

The Oncology Institute

Social

Jul 9

Bullish· Mar 13

Bearish· Feb 12

Announcements· Apr 25

Macro· Apr 25

Technical Analysis· Mar 13

Regulars· Nov 14

Newcomers· Jul 9

Starling Oncology Institute Secures New $25 Million Credit Facility

Oncology Institute Q2 Earnings Call Highlights

The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates

Earnings To Watch: Starling Oncology Inc (STLN) Q2 2026 -- GF Value Sees 44% Downside

The Oncology Institute Changes Name to Starling Oncology

The Oncology Institute Rebrands as Starling Oncology

Also Discussed

The Oncology Institute Inc.

Company Information

Location

Starling Oncology Institute Secures New $25 Million Credit Facility

Oncology Institute Q2 Earnings Call Highlights

The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates

Earnings To Watch: Starling Oncology Inc (STLN) Q2 2026 -- GF Value Sees 44% Downside

The Oncology Institute Changes Name to Starling Oncology

The Oncology Institute Rebrands as Starling Oncology

Also Discussed

Social

Jul 9

Bullish· Mar 13

Bearish· Feb 12

Announcements· Apr 25

Macro· Apr 25

Technical Analysis· Mar 13

Regulars· Nov 14

Newcomers· Jul 9